ESGCT 2025 | British Society for Gene & Cell Therapy

Collaborative. That’s the word Gerry McLachlan from the British Society for Gene & Cell Therapy used to describe the heart of BSGCT—and I couldn't agree more!

I had a great conversation with Gerry at #ESGCT2025 about the evolution of gene therapy over the past 25 years, breakthroughs in genome editing, and clinical advances like the lentiviral therapy for cystic fibrosis currently in trials with Boehringer Ingelheim. He also highlighted how BSGCT supports the next generation of scientists through travel awards, research bursaries, and networking opportunities, while bridging academia and industry to help turn lab discoveries into real-world therapies.

Watch the full interview to hear Gerry’s insights on advancing gene therapy, supporting early career researchers, and translating breakthroughs from lab to clinic. 🌟